Preliminary data show BiondVax flu vaccine M-001 to be well-tolerated in mid-stage European study

|By:, SA News Editor

Although the data is still blinded, preliminary results from BiondVax Pharmaceuticals' (BVXV -0.9%) Europe-based Phase 2 study assessing universal flu vaccine candidate M-001 show it to be safe and well-tolerated. Only three moderate adverse events have been observed thus far.

The study is designed to compare the safety and immunogenicity of M-001 to placebo (saline) and then the standard H5N1 avian pandemic vaccine and an experimental group receiving M-001 as primer prior to receiving the same H5N1 pandemic vaccine.

According to ClinicalTrials.gov, the estimated study completion date is January 2017.